



Attorney's Docket No.: 06275-276002 / LDG/Z70675-2 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John Craig Smith
Serial No. : 10/621,116
Filed : July 16, 2003
Title : DIAGNOSTIC METHOD

Art Unit : 1634
Examiner : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

Under 35 USC §120, the application relies on the earlier filing date of application serial number 09/778,900, filed February 8, 2001. The following references were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application:

Desig. IDs: AB, AG, AH, AJ, AN, AP and AU.

This statement is being filed before the receipt of a first Office action on the merits. No fees are believed to be due. If any charges or credits are incurred, please apply them to Deposit Account No. 06-1050 with reference to Attorney Docket No. 06275-276002.

Respectfully submitted,

Date: January 23, 2004

Robert L. Hahn Reg. No: 54,154
Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20793067.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL
I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1-26-2004
Date of Deposit

Signature

Roberta L. Hahn
Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 06275-276002	Application No. 10/621,116
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))				Applicant John Craig Smith	
				Filing Date July 16, 2003	Group Art Unit 1634

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AB	WO 99/52942	1999	WIPO			
	AC						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AD	Arora <i>et al.</i> , "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells," <i>Cancer Research</i> 59:183-188 (1999)
	AE	Fong <i>et al.</i> , "Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium," <i>Nature</i> 376:66-70 (1995)
	AF	Fong <i>et al.</i> , "SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types," <i>Cancer Research</i> 59:99-106 (1999)
	AG	Hacker <i>et al.</i> , "Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis," <i>Gut</i> , 40:623-627 (1997)
	AH	Ikeda <i>et al.</i> , "Characterization of the Promoter Region for <i>flt-1</i> Tyrosine Kinase Gene, A Receptor for Vascular Endothelial Growth Factor," <i>Growth Factors</i> 13:151-162 (1996)
	AI	Ito <i>et al.</i> , "Identification of Vascular Endothelial Growth Factor Receptor-1 Tyrosine Phosphorylation Sites and Binding of SH2 Domain-containing Molecules," <i>J. Biol. Chem.</i> 273:23410-23418 (1998)
	AJ	Kondo <i>et al.</i> , "Genomic organization of the <i>flt-1</i> gene encoding for Vascular Endothelial Growth Factor (VEGF) Receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors," <i>Gene</i> 208:297-305 (1998)
	AK	Kong <i>et al.</i> , "Regional suppression of tumor growth by <i>in vivo</i> transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor," <i>Human Gene Therapy</i> 9:823-833 (1998)
	AL	Morishita <i>et al.</i> , "A Novel Promoter for Vascular Endothelial Growth Factor Receptor (flt-1) That Confers Endothelial-specific Gene Expression," <i>J. Biol. Chem.</i> 270:27948-27953 (1995)
	AM	Neufeld <i>et al.</i> , "Vascular endothelial growth factor (VEGF) and its receptors," <i>FASEB Journal</i> 13:11-22 (1999)
	AN	Parry <i>et al.</i> , "Dinucleotide repeat polymorphisms within the Flt-1 gene in minimal change nephropathy," <i>European J. Immunogenetics</i> 26:321-323 (1999)
	AO	Parry <i>et al.</i> , "Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA," <i>Nucleic Acids Research</i> 27:2569-2577 (1999)
	AP	Pennisi, "A Closer Look at SNPs Suggests Difficulties," <i>Science</i> 281:1787-1789 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. JAN 29 2003 John Craig Smith	Application No. 10/621,116
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date July 16, 2003	Group Art Unit 1634

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AQ	Rosnet <i>et al.</i> , "Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse," <i>Oncogene</i> 8:173-179 (1993)
	AR	Ruckman <i>et al.</i> , "2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain," <i>J. Biol. Chem.</i> 273:20556-20567 (1998)
	AS	Shen <i>et al.</i> , "Single-nucleotide polymorphisms can cause different structural folds of mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 96:7871-7876 (1999)
	AT	Skobe <i>et al.</i> , "Halting angiogenesis suppresses carcinoma cell invasion," <i>Nature Medicine</i> 3:1222-1227 (1997)
	AU	Shibuya <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 5(4):519-524 (1990)
	AV	Zachary, "Vascular endothelial growth factor: how it transmits its signal," <i>Experimental Nephrology</i> 6:480-487 (1998)
	AW	
	AX	
	AY	
	AZ	
	AAA	
	ABB	
	ACC	
	ADD	
	AEE	
	AFF	
	AGG	
	AHH	
	AII	
	AJJ	
	AKK	
	ALL	
	AMM	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	